Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $22.0 million.

  • Syndax Pharmaceuticals' Non-Current Assets rose 9961.83% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.2 million, marking a year-over-year increase of 8411.17%. This contributed to the annual value of $121.8 million for FY2024, which is 28044.93% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Non-Current Assets of $22.0 million as of Q3 2025, which was up 9961.83% from $64.5 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Non-Current Assets high stood at $121.8 million for Q4 2024, and its period low was $504000.0 during Q2 2021.
  • In the last 5 years, Syndax Pharmaceuticals' Non-Current Assets had a median value of $18.2 million in 2023 and averaged $29.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 270753.97% in 2022, then tumbled by 3971.51% in 2024.
  • Syndax Pharmaceuticals' Non-Current Assets (Quarter) stood at $1.3 million in 2021, then surged by 490.8% to $7.4 million in 2022, then skyrocketed by 329.58% to $32.0 million in 2023, then surged by 280.45% to $121.8 million in 2024, then crashed by 81.96% to $22.0 million in 2025.
  • Its Non-Current Assets stands at $22.0 million for Q3 2025, versus $64.5 million for Q2 2025 and $92.0 million for Q1 2025.